Abstract: Endometrial cancer is the second most common malignancy in women after breast cancer. The staging of the disease is solely surgical so the information concerning the lymph node status is crucial for the postoperative treatment and prognosis. Aim. The aim of the study was to determine the feasibility of sentinel lymph node detection in patients with endometrial cancer stage I, via injecting patent blue in the uterine cervix. Materials and methods. The study includes 58 patients with endometrial cancer. The technique includes 4 ml of blue dye administered intracervical at two sites-3 and 9 o'clock. After 20 min sentinel lymph nodes were detected. Results. Lymph nodes were detected in 52 patients and in only 6 patients the method was unsuccessful thus leaving the detection rate at 89.65 % Conclusion. This method for detection of sentinel lymph nodes in patients with endometrial cancer is promising, fast and easy to implement, but additional studies must be done for it to become part of the standard for surgical treatment of endometrial cancer.
According to the FIGO stage I the risk of LNM occurrence is 10-12% and the risk for para-aortic LNM is 4-6%. 2 The LN dissection could be either selective or total-for example selective LN dissection is performed in Europe, whereas in the USA the method of choice is total LN dissection. Because of this the idea of sentinel LN biopsy is so convenient. The first report about SLN detection was done by Burke et al in 1996. 3 AIM: The aim of the study was to determine the feasibility of sentinel lymph node detection in patients with endometrial cancer stage I, via injecting patent blue in the uterine cervix.
MATERIALS AND METHODS:
58 patients were included in this study for the period September 2014-august 2016 (23 months). Criteria for inclusion were stage I endometrial cancer and informed concern of the patients. Criteria for exclusion were medical history for allergies (patent blue V could lead to various allergic reactions), previous surgery that could change the uterine lymphatic drainage and patient refusal. After the induction of anesthesia the color agent was injected intracervical with 25 gauge spinal needle at 3 and 9 o'clock positions (2 ml per injection). The SLN are detected after 20 minutes and total LN dissection is performed by an open (28 cases) or robotic (30 cases) approach. We inspected the pelvic and paraaortal regions for colored LNs and lymph channels. Dissection of all blue colored LNs and LNs connected to blue colored lymph channels was made. We recorded the position of all SLNs to the major pelvic vessels. We did not find any SLNs in the para-aortic region. Total hysterectomy with different type of LN dissection was performed on all patients. The risk of LN metastasis is determined from the preoperative clinical data and the intraoperative findings. According to this system either total or selective LN dissection was done.
RESULTS
58 patients with endometrial cancer stage I were treated in our clinic. 28 patients were treated by open approach with success rate 100%. 30 patients were treated by robotic approach, 6 of which were unsuccessful (success rate 80%). Demographic for the open approach-there was one patient with undetected SLN in the left hemipelvis. For the 6 unsuccesful cases the SLN was not detected on both sides. There was no detection of para-aortic SLNs in any of the cases. All of the dissected LNs are from the pelvic area. Table 2 shows the number of all removed LNs as well as the number of removed SLNs (the total number and separately for the left and and right hemipelvis, respectively). In two cases-one from each group-the metastatic SLNs were detected from both sides and the following non SLNs were also metastatic. In one case from the open approach there were metastatic SLNs from both sides but the metastatic non SLN were only from the right side. The forth case is with metastatic SLNs only from the right hemipelvis and with no metastatic SLNs from either side. In all other 48 cases neither the SLNs, nor the non SLNs were non-metastatic from both sides. After the histological results, the patients were grouped by the following criteria: grading, myometrial invasion (MI) and tumor diameter (TD)-figure 4 The results are shown in Table 5 Six of the cases (10.34%) were unsuccessful. All of them were in the group of the robotic approach. This could be due to the lack of experience because all six unsuccessful operations were done in the beginning of this study. The results of our study suggest that SLN biopsy by use of cervical injection of patent blue V could take place between systemic lymphnodectomy and no dissection at all in patients with low and intermediate risk for endometrial cancer. Our results are in accordance with the previous publications, concerning this topic-detection rate 83-84%. (6, 7) The cervical injection of radiocolloid improves the success rate, as cited in literature-91-100% (8, 9) . Some authors suggest the injection of patent blue V in the subserosal myometrium because of the direct drainage of the uterine fundus via the gonadal vessels. (3) The risk of para-aortic LNM is very low in first stage endometrial cancer. (3) We used cervical injection of patent blue V because it is an easy method to learn and we had previous experience in detection SLN in patients with cervical cancer. In this research no false negative cases were found, sensitivity and negative predictive value (NPV) were 100%. 
